Connective tissue growth factor is a substrate of ADAM28

Biochemical and Biophysical Research Communications

Volumn 402, Issue 4, 2010, Pages 651-657

  Mochizuki, Satsuki ^a   Tanaka, Rena ^a   Shimoda, Masayuki ^a   Onuma, Junko ^a   Fujii, Yutaka ^b   Jinno, Hiromitsu ^a   Okada, Yasunori ^a  

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

A disintegrin and metalloproteinase; Angiogenesis; Connective tissue growth factor; Digestion; Vascular endothelial growth factor

Indexed keywords

ADAM PROTEIN; ADAM28 PROTEIN; ALANINE; ASPARAGINE; COMPLEMENTARY DNA; CONNECTIVE TISSUE GROWTH FACTOR; PROLINE; TYROSINE; UNCLASSIFIED DRUG; VASCULOTROPIN 165;

ANGIOGENESIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER TISSUE; CONTROLLED STUDY; DNA LIBRARY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO HYBRID SYSTEM; YEAST;

ADAM PROTEINS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; SUBSTRATE SPECIFICITY; TWO-HYBRID SYSTEM TECHNIQUES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649449540     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.077     Document Type: Article

References (33)

1. Seals D.F., Courtneidge S.A. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 2003, 17:7-30.
2. Edwards D.R., Handsley M.M., Pennington C.J. The ADAM metalloproteinases. Mol. Aspects Med. 2008, 29:258-289.
3. Murphy G. Regulation of the proteolytic disintegrin metalloproteinases, the 'Sheddases'. Semin. Cell Dev. Biol. 2009, 20:138-145.
4. Roberts C.M., Tani P.H., Bridges L.C., Laszik Z., Bowditch R.D. MDC-L, a novel metalloprotease disintegrin cysteine-rich protein family member expressed by human lymphocytes. J. Biol. Chem. 1999, 274:29251-29259.
5. Shiomi T., Lemaitre V., D'Armiento J., Okada Y. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Pathol. Int. 2010, 60:477-496.
6. Mochizuki S., Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci. 2007, 98:621-628.
7. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat. Rev. Cancer 2008, 8:929-941.
8. Mitsui Y., Mochizuki S., Kodama T., Shimoda M., Ohtsuka T., Shiomi T., Chijiiwa M., Ikeda T., Kitajima M., Okada Y. ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res. 2006, 66:9913-9920.
9. Ohtsuka T., Shiomi T., Shimoda M., Kodama T., Amour A., Murphy G., Ohuchi E., Kobayashi K., Okada Y. ADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasis. Int. J. Cancer 2006, 118:263-273.
10. Kuroda H., Mochizuki S., Shimoda M., Chijiiwa M., Kamiya K., Izumi Y., Watanabe M., Horinouchi H., Kawamura M., Kobayashi K., Okada Y. ADAM28 is a serological and histochemical marker for non-small-cell lung cancers. Int. J. Cancer 2010, 127:1844-1856.
11. Howard L., Zheng Y., Horrocks M., Maciewicz R.A., Blobel C. Catalytic activity of ADAM28. FEBS Lett. 2001, 498:82-86.
12. Fourie A.M., Coles F., Moreno V., Karlsson L. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J. Biol. Chem. 2003, 278:30469-30477.
13. Mochizuki S., Shimoda M., Shiomi T., Fujii Y., Okada Y. ADAM28 is activated by MMP-7 (matrilysin-1) and cleaves insulin-like growth factor binding protein-3. Biochem. Biophys. Res. Commun. 2004, 315:79-84.
14. Hikichi Y., Yoshimura K., Takigawa M. All-trans retinoic acid-induced ADAM28 degrades proteoglycans in human chondrocytes. Biochem. Biophys. Res. Commun. 2009, 386:294-299.
15. Mochizuki S., Okada Y. ADAM28 as a target for human cancers. Curr. Pharm. Des. 2009, 15:2349-2358.
16. Shimoda M., Hashimoto G., Mochizuki S., Ikeda E., Nagai N., Ishida S., Okada Y. Binding of ADAM28 to P-selectin glycoprotein ligand-1 enhances P-selectin-mediated leukocyte adhesion to endothelial cells. J. Biol. Chem. 2007, 282:25864-25874.
17. Hashimoto G., Shimoda M., Okada Y. ADAMTS4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. J. Biol. Chem. 2004, 279:32483-32491.
18. Inoki I., Shiomi T., Hashimoto G., Enomoto H., Nakamura H., Makino K., Ikeda E., Takata S., Kobayashi K., Okada Y. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002, 16:219-221.
19. Hashimoto G., Inoki I., Fujii Y., Aoki T., Ikeda E., Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J. Biol. Chem. 2002, 277:36288-36295.
20. Bridges L.C., Bowditch R.D. ADAM-integrin interactions: potential integrin regulated ectodomain shedding activity. Curr. Pharm. Des. 2005, 11:837-847.
21. Takeda S., Igarashi T., Mori H., Araki S. Crystal structures of VAP1 reveal ADAMs' MDC domain architecture and its unique C-shaped scaffold. EMBO J. 2006, 25:2388-2396.
22. Chang C.C., Shih J.Y., Jeng Y.M., Su J.L., Lin B.Z., Chen S.T., Chau Y.P., Yang P.C., Kuo M.L. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J. Natl. Cancer Inst. 2004, 96:364-375.
23. Enomoto H., Inoki I., Komiya K., Shiomi T., Ikeda E., Obata K., Matsumoto H., Toyama Y., Okada Y. Vascular endothelial growth factor isoforms and their receptors are expressed in human osteoarthritic cartilage. Am. J. Pathol. 2003, 162:171-181.
24. Chen C.C., Lau L.F. Functions and mechanisms of action of CCN matricellular proteins. Int. J. Biochem. Cell Biol. 2009, 41:771-783.
25. Brigstock D.R. The CCN family: a new stimulus package. J. Endocrinol. 2003, 178:169-175.
26. Shi-Wen X., Leask A., Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev. 2008, 19:133-144.
27. Dean R.A., Butler G.S., Hamma-Kourbali Y., Delbe J., Brigstock D.R., Courty J., Overall C.M. Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol. Cell Biol. 2007, 27:8454-8465.
28. Tam E.M., Morrison C.J., Wu Y.I., Stack M.S., Overall C.M. Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc. Natl. Acad. Sci. USA 2004, 101:6917-6922.
29. Guo S., Colbert L.S., Fuller M., Zhang Y., Gonzalez-Perez R.R. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim. Biophys. Acta 2010, 1806:108-121.
30. Relf M., LeJeune S., Scott P.A., Fox S., Smith K., Leek R., Moghaddam A., Whitehouse R., Bicknell R., Harris A.L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res. 1997, 57:963-969.
31. Moussad E.E., Brigstock D.R. Connective tissue growth factor: what's in a name?. Mol. Genet. Metab. 2000, 71:276-292.
32. Xie D., Nakachi K., Wang H., Elashoff R., Koeffler H.P. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 2001, 61:8917-8923.
33. Chu C.Y., Chang C.C., Prakash E., Kuo M.L. Connective tissue growth factor (CTGF) and cancer progression. J. Biomed. Sci. 2008, 15:675-685.